摘要
肾细胞癌是我国泌尿生殖系统最常见的肿瘤之一。约30%的肾细胞癌患者在就诊时或手术后可能出现转移,预后差。转移性肾细胞癌对放疗与化疗均不敏感。转移性肾癌的分子靶向治疗已经取得了显著进展。现将最新的相关进展进行总结。
Renal cell carcinoma （RCC） is the most common cancer of kidney in China. Up to 30% of patients with RCC present with metastatic disease, and recurrence develops in approximately 30% of patients treated for a localized tumor. RCC is highly resistant to chemotherapy and radiotherapy. Highdose IL - 2 therapy or interferon alfa is widely used as the first - line treatment of metastatic renal cell carcinoma （mRCC）, While the response rates remain low （5% -20% ）. The molecularly targeted therapy of mRCC has made dramatical progress in recent years, which will be summarized in this article.
出处
《癌症进展》
2007年第6期517-524,共8页
Oncology Progress
关键词
转移性肾细胞癌
分子靶向治疗
metastatic renal cell carcinoma （mRCC） molecularly targeted therapy
